Maple Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Maple Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-16,305	Closed	-$1.84M	–	123
2015 Q4	$1.84M	Sell	16,305 -1,566	-9%	-$170K	0.65%	46
2015 Q3	$1.81M	Sell	17,871 -4,488	-20%	-$538K	0.67%	48
2015 Q2	$2.75M	Buy	22,359 +7,365	+49%	+$882K	0.94%	44
2015 Q1	$1.72M	Buy	14,994 +8,034	+115%	+$886K	0.6%	50
2014 Q4	$704K	Buy	6,960 +2,685	+63%	+$261K	0.25%	72
2014 Q3	$390K	Buy	4,275 +600	+16%	+$52.7K	0.15%	83
2014 Q2	$315K	Sell	3,675 -150	-4%	-$11.8K	0.11%	101
2014 Q1	$301K	Hold	3,825	–	–	0.12%	104
2013 Q4	$290K	Hold	3,825	–	–	0.12%	109
2013 Q3	$267K	Hold	3,825	–	–	0.12%	107
2013 Q2	$222K	Buy	+3,825	New	+$221K	0.1%	111

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Maple Capital Management's IBB Position: Q1 2016 in Review

Maple Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2016, closing a stake of 16,305 shares — an estimated $1.84M sold.

Maple Capital Management first reported a position in IBB in Q2 2013 and held it in 11 quarters. The position peaked at $2.75M in Q2 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

Maple Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2016 after selling out during the quarter.
Maple Capital Management sold 16,305 iShares Biotechnology ETF shares in Q1 2016, an estimated $1.84M.
Maple Capital Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 11 quarters.
Maple Capital Management's iShares Biotechnology ETF position peaked at $2.75M in Q2 2015.
415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Maple Capital Management's 13F filing for Q1 2016, filed 13 May 2016.